LL-37 (17-29) [V21L]-Ac

General Information


DRACP ID  DRACP02884

Peptide Name   LL-37 (17-29) [V21L]-Ac

Sequence  FKRILQRIKDFLR

Sequence Length  13

UniProt ID  P49913 

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
A549 Lung adenocarcinoma Carcinoma IC50=29.2 μg/ml MTT assay 24 h 1

Hemolytic Activity  Human erythrocytes: Not active up to 500 µg/ml

Normal (non-cancerous) Cytotoxicity  DLF lung fibroblasts: IC50=160.9 μg/ml

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antibacterial; Antifungal



Structure Information


PDB ID  Not available

Predicted Structure  DRACP02884

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Acetylation

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C81H137N25O17

Absent amino acids  ACEGHMNPSTVWY

Common amino acids  R

Mass  194736

Pl  12.24

Basic residues  5

Acidic residues  1

Hydrophobic residues  6

Net charge  4

Boman Index  -4448

Hydrophobicity  -46.92

Aliphatic Index  120

Half Life 
  Mammalian: 1.1 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  0

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 32567085

Title  Cationic amphipathic peptide analogs of cathelicidin LL-37 as a probe in the development of antimicrobial/anticancer agents

Doi 10.1002/psc.3254

Year  2020

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  DBAASPS_17802

DRACP is developed by Dr.Zheng's team.